CN120643579A - 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物 - Google Patents

使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Info

Publication number
CN120643579A
CN120643579A CN202511095571.2A CN202511095571A CN120643579A CN 120643579 A CN120643579 A CN 120643579A CN 202511095571 A CN202511095571 A CN 202511095571A CN 120643579 A CN120643579 A CN 120643579A
Authority
CN
China
Prior art keywords
sialyllactose
group
peroxisome proliferator
activated receptor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511095571.2A
Other languages
English (en)
Chinese (zh)
Inventor
康丞雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Benebiosis Co Ltd
Original Assignee
Benebiosis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benebiosis Co Ltd filed Critical Benebiosis Co Ltd
Publication of CN120643579A publication Critical patent/CN120643579A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
CN202511095571.2A 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物 Pending CN120643579A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2016-0004383 2016-01-13
KR20160004383 2016-01-13
PCT/KR2017/000505 WO2017123066A1 (ko) 2016-01-13 2017-01-13 Pgc-1알파의 발현을 증가시키는 조성물
CN201780006641.XA CN108472305A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780006641.XA Division CN108472305A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Publications (1)

Publication Number Publication Date
CN120643579A true CN120643579A (zh) 2025-09-16

Family

ID=59311711

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201780006641.XA Pending CN108472305A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物
CN202511095689.5A Pending CN120661527A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物
CN202511095571.2A Pending CN120643579A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201780006641.XA Pending CN108472305A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物
CN202511095689.5A Pending CN120661527A (zh) 2016-01-13 2017-01-13 使过氧化物酶体增殖物激活受体共激活因子1-α的表达增加的组合物

Country Status (12)

Country Link
US (1) US20190030053A1 (enExample)
EP (2) EP3845233A1 (enExample)
JP (3) JP7125348B2 (enExample)
KR (3) KR102771814B1 (enExample)
CN (3) CN108472305A (enExample)
CA (2) CA3203927A1 (enExample)
ES (1) ES2946945T3 (enExample)
HK (1) HK1257689A1 (enExample)
MX (2) MX389553B (enExample)
MY (1) MY197561A (enExample)
SG (1) SG11201805791RA (enExample)
WO (1) WO2017123066A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3498282A1 (en) 2017-12-12 2019-06-19 Rheinische Friedrich-Wilhelms-Universität Bonn 6'-sialyllactose for use in the treatment of hearing loss
US11234992B2 (en) * 2018-02-28 2022-02-01 The Regents Of The University Of California Methods and therapies for treating atherosclerosis and/or hyperlipidemia using oligosaccharides
EP3934657A4 (en) * 2019-03-05 2023-01-04 Glycom A/S HUMAN MILK OLYGOSACCHARIDES TO IMPROVE EXECUTION FUNCTION
CN113518622A (zh) * 2019-03-05 2021-10-19 雀巢产品有限公司 用于增强执行功能的营养组合物
JP2021038147A (ja) * 2019-08-30 2021-03-11 国立大学法人 鹿児島大学 ミトコンドリア生合成促進剤
KR102186761B1 (ko) * 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
GB202114190D0 (en) * 2021-10-04 2021-11-17 Mjn Us Holdings Llc Compositions for preventing and/or treating demyelination
WO2024246686A1 (en) * 2023-06-02 2024-12-05 Zydus Lifesciences Limited Treatment for amyotrophic lateral sclerosis (als)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
JPH07258093A (ja) * 1994-03-23 1995-10-09 Morinaga Milk Ind Co Ltd 神経成長因子様剤
KR101116864B1 (ko) * 2008-08-01 2012-02-29 주식회사 베네비오 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물
KR101112051B1 (ko) * 2009-04-09 2012-02-14 주식회사 베네비오 비후성 반흔 또는 켈로이드 예방 또는 치료용 조성물
KR20110092602A (ko) * 2010-02-09 2011-08-18 주식회사 베네비오 플라스미노겐 활성 억제인자-1의 억제제
MY171620A (en) * 2010-12-31 2019-10-21 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers or children using human milk oligosaccharides
CN104620605B (zh) * 2012-09-14 2018-03-30 罗伯特·博世有限公司 使用声学端口阻挡的装置测试
CA2893217C (en) 2012-12-18 2017-11-28 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
HK1215521A1 (zh) * 2012-12-18 2016-09-02 Abbott Laboratories 包含神经保护膳食寡糖的营养组合物
DE102013208103A1 (de) 2013-05-03 2014-11-06 Siemens Aktiengesellschaft Röntgenquelle und bildgebendes System
WO2016145628A1 (en) * 2015-03-18 2016-09-22 Nestec S.A. Composition comprising siallyllactose for use in enhancing learning skills and memory function

Also Published As

Publication number Publication date
KR20210079376A (ko) 2021-06-29
RU2018128408A (ru) 2020-02-13
SG11201805791RA (en) 2018-08-30
CA3010338A1 (en) 2017-07-20
MX2022000945A (es) 2022-02-14
ES2946945T3 (es) 2023-07-28
JP2024081767A (ja) 2024-06-18
WO2017123066A1 (ko) 2017-07-20
MX389553B (es) 2025-03-20
CA3010338C (en) 2023-08-22
CA3203927A1 (en) 2017-07-20
EP3403655A1 (en) 2018-11-21
RU2018128408A3 (enExample) 2020-02-13
EP3403655C0 (en) 2023-06-07
CN108472305A (zh) 2018-08-31
EP3403655B1 (en) 2023-06-07
MY197561A (en) 2023-06-23
KR20180099885A (ko) 2018-09-05
MX2018008671A (es) 2019-02-13
US20190030053A1 (en) 2019-01-31
EP3845233A1 (en) 2021-07-07
KR102771814B1 (ko) 2025-02-26
EP3403655A4 (en) 2019-08-07
CN120661527A (zh) 2025-09-19
JP2022166164A (ja) 2022-11-01
JP7125348B2 (ja) 2022-08-24
HK1257689A1 (zh) 2019-10-25
JP7467543B2 (ja) 2024-04-15
KR20230107718A (ko) 2023-07-17
JP2019502718A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
JP7467543B2 (ja) ＰＧＣ－１αの発現を増加させる組成物
EP2152281B1 (en) Cosmetic use of ginseng berry extract for skin whitening
JP7564568B2 (ja) 皮膚用組成物
US20080020988A1 (en) Brain cell- or nerve cell-protecting agents comprising medicinal ginseng
JP5685315B2 (ja) ニコチン酸アデニンディヌクレオチドリン酸又はその誘導体を含む薬学又は化粧料組成物
JP2017502087A (ja) 化粧品組成物、皮膚科学組成物、または栄養化粧品組成物に使用するショ糖エステルを有効成分として含有する植物抽出物
RU2647600C2 (ru) Активатор трансглутаминазы
TW202102242A (zh) 余甘子萃取發酵物及其製備與應用
JP2007182444A (ja) ハッカの抽出物の化粧的使用
RU2814560C2 (ru) КОМПОЗИЦИЯ ДЛЯ ПОВЫШЕНИЯ ЭКСПРЕССИИ PGC-1α
JP5392742B2 (ja) メラニン生成阻害剤
US20150290105A1 (en) Composition comprising syringaresinol for improving the skin
JP6368219B2 (ja) エストロゲン受容体β活性化剤
EP3777865A1 (en) Anti-aging composition
JP2018138524A (ja) 時計遺伝子発現調整剤、及びこれを含有する概日リズム調整剤
CN118043048A (zh) M2或m2样巨噬细胞的诱导或激活剂、m2或m2样巨噬细胞的诱导或激活方法、用于预防和/或改善真皮的色素沉积的组合物、以及预防和/或改善真皮的色素沉积的方法
KR20250092491A (ko) 애플망고 추출물을 유효성분으로 함유하는 피부 미백용 조성물
JP2018070566A (ja) メラニン分解促進剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination